EyePoint Pharmaceuticals (NASDAQ:EYPT) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

EyePoint Pharmaceuticals (NASDAQ:EYPT) issued its quarterly earnings results on Wednesday. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10), Zacks reports. The business had revenue of $11.60 million for the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%.

EyePoint Pharmaceuticals Stock Performance

Shares of EYPT opened at $6.82 on Friday. The firm has a market cap of $465.47 million, a PE ratio of -3.41 and a beta of 1.51. EyePoint Pharmaceuticals has a 52-week low of $5.54 and a 52-week high of $26.76. The business’s 50 day moving average price is $7.27 and its two-hundred day moving average price is $8.47.

Analyst Upgrades and Downgrades

Several brokerages have commented on EYPT. Robert W. Baird cut their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. Citigroup started coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday. Finally, Chardan Capital restated a “buy” rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.